Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDTX NASDAQ:IMTX NASDAQ:RLAY NASDAQ:RZLT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$2.94+2.4%$2.78$1.20▼$6.33$167.39M2.93772,637 shs602,435 shsIMTXImmatics$6.26+9.4%$5.95$3.30▼$13.09$760.90M1.02823,409 shs3.22 million shsRLAYRelay Therapeutics$4.12+3.0%$3.59$1.77▼$10.72$710.33M1.61.40 million shs2.03 million shsRZLTRezolute$8.00+8.4%$6.03$2.21▼$8.06$695.97M0.03738,004 shs1.56 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics+2.44%+6.91%+9.29%+13.95%-47.69%IMTXImmatics+9.44%+22.99%-1.26%+4.86%-44.31%RLAYRelay Therapeutics+3.00%+14.76%+16.71%+22.62%-35.12%RZLTRezolute+8.40%+12.36%+40.60%+80.59%+70.21%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$2.94+2.4%$2.78$1.20▼$6.33$167.39M2.93772,637 shs602,435 shsIMTXImmatics$6.26+9.4%$5.95$3.30▼$13.09$760.90M1.02823,409 shs3.22 million shsRLAYRelay Therapeutics$4.12+3.0%$3.59$1.77▼$10.72$710.33M1.61.40 million shs2.03 million shsRZLTRezolute$8.00+8.4%$6.03$2.21▼$8.06$695.97M0.03738,004 shs1.56 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics+2.44%+6.91%+9.29%+13.95%-47.69%IMTXImmatics+9.44%+22.99%-1.26%+4.86%-44.31%RLAYRelay Therapeutics+3.00%+14.76%+16.71%+22.62%-35.12%RZLTRezolute+8.40%+12.36%+40.60%+80.59%+70.21%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDTXBlack Diamond Therapeutics 3.14Buy$11.67296.83% UpsideIMTXImmatics 2.83Moderate Buy$14.67134.29% UpsideRLAYRelay Therapeutics 2.92Moderate Buy$17.50324.76% UpsideRZLTRezolute 3.17Buy$12.5056.25% UpsideCurrent Analyst Ratings BreakdownLatest BDTX, RZLT, RLAY, and IMTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/4/2025RLAYRelay TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$15.009/3/2025BDTXBlack Diamond TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$8.009/3/2025BDTXBlack Diamond TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$8.009/3/2025RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.008/26/2025RLAYRelay TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$16.00 ➝ $14.008/15/2025IMTXImmaticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell8/11/2025BDTXBlack Diamond TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/11/2025BDTXBlack Diamond TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $10.008/8/2025RLAYRelay TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetStrong-Buy$29.00 ➝ $19.007/1/2025BDTXBlack Diamond TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform$11.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDTXBlack Diamond TherapeuticsN/AN/AN/AN/A$1.47 per shareN/AIMTXImmatics$168.65M4.51$0.24 per share25.62$5.12 per share1.22RLAYRelay Therapeutics$10.01M70.96N/AN/A$4.65 per share0.89RZLTRezoluteN/AN/AN/AN/A$2.19 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDTXBlack Diamond Therapeutics-$69.68M$0.2312.78N/AN/AN/A12.70%9.58%11/4/2025 (Estimated)IMTXImmatics$16.47M-$0.65N/AN/AN/A-59.29%-15.60%-12.31%11/17/2025 (Estimated)RLAYRelay Therapeutics-$337.71M-$1.95N/AN/AN/AN/A-41.49%-37.43%11/5/2025 (Estimated)RZLTRezolute-$68.46M-$1.15N/AN/AN/AN/A-70.09%-63.08%9/18/2025 (Estimated)Latest BDTX, RZLT, RLAY, and IMTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/18/2025Q4 2025RZLTRezolute-$0.22N/AN/AN/AN/AN/A8/13/2025Q1 2025IMTXImmatics-$0.38-$0.66-$0.28-$0.66$13.05 million$6.48 million8/7/2025Q2 2025BDTXBlack Diamond Therapeutics-$0.25-$0.19+$0.06-$0.19N/AN/A8/7/2025Q2 2025RLAYRelay Therapeutics-$0.49-$0.41+$0.08-$0.41$0.07 million$0.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBDTXBlack Diamond TherapeuticsN/AN/AN/AN/AN/AIMTXImmaticsN/AN/AN/AN/AN/ARLAYRelay TherapeuticsN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDTXBlack Diamond TherapeuticsN/A8.738.73IMTXImmaticsN/A8.808.80RLAYRelay TherapeuticsN/A20.9220.92RZLTRezoluteN/A8.438.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDTXBlack Diamond Therapeutics95.47%IMTXImmatics64.41%RLAYRelay Therapeutics96.98%RZLTRezolute82.97%Insider OwnershipCompanyInsider OwnershipBDTXBlack Diamond Therapeutics5.97%IMTXImmatics3.30%RLAYRelay Therapeutics4.87%RZLTRezolute18.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDTXBlack Diamond Therapeutics9056.94 million53.54 millionOptionableIMTXImmatics260121.55 million117.54 millionOptionableRLAYRelay Therapeutics330172.41 million164.02 millionOptionableRZLTRezolute4087.00 million71.00 millionOptionableBDTX, RZLT, RLAY, and IMTX HeadlinesRecent News About These CompaniesRezolute, Inc. $RZLT Shares Bought by OMERS ADMINISTRATION CorpSeptember 6 at 4:43 AM | marketbeat.comRezolute (NASDAQ:RZLT) Earns "Buy" Rating from HC WainwrightSeptember 6 at 2:59 AM | americanbankingnews.comRezolute, Inc. (NASDAQ:RZLT) Given Consensus Recommendation of "Buy" by AnalystsSeptember 5 at 10:20 AM | marketbeat.comRezolute (NASDAQ:RZLT) Receives "Buy" Rating from HC WainwrightSeptember 5 at 8:25 AM | marketbeat.comADAR1 Capital Management LLC Cuts Stock Position in Rezolute, Inc. $RZLTSeptember 4 at 7:42 AM | marketbeat.comNantahala Capital Management LLC Sells 1,566,587 Shares of Rezolute, Inc. $RZLTSeptember 3 at 7:08 AM | marketbeat.comRezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor HyperinsulinismSeptember 2, 2025 | globenewswire.comRezolute Aligns with FDA on Phase 3 Trial DesignSeptember 2, 2025 | tipranks.comVelan Capital Investment Management LP Reduces Stock Holdings in Rezolute, Inc. $RZLTAugust 31, 2025 | marketbeat.comAffinity Asset Advisors LLC Buys 125,000 Shares of Rezolute, Inc. $RZLTAugust 28, 2025 | marketbeat.comRezolute (NASDAQ:RZLT) Hits New 52-Week High - Still a Buy?August 27, 2025 | marketbeat.comRezolute, Inc. to Present at Upcoming Investor Conferences in September 2025August 27, 2025 | quiverquant.comQRezolute to Participate in Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.comRezolute appoints Karnawat as Chief Commercial OfficerAugust 20, 2025 | msn.comRezolute Appoints New Chief Commercial OfficerAugust 20, 2025 | msn.comRezolute (NASDAQ:RZLT) Hits New 52-Week High - What's Next?August 20, 2025 | marketbeat.comRezolute, Inc. Appoints Sunil Karnawat as Chief Commercial Officer to Advance Commercialization of ersodetugAugust 20, 2025 | quiverquant.comQRezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial OfficerAugust 20, 2025 | globenewswire.comAltium Capital Management LLC Has $881,000 Position in Rezolute, Inc. (NASDAQ:RZLT)August 14, 2025 | marketbeat.comVivo Capital LLC Sells 685,272 Shares of Rezolute, Inc. (NASDAQ:RZLT)August 9, 2025 | marketbeat.comRezolute to Participate in the BTIG Virtual Biotechnology ConferenceJuly 22, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBDTX, RZLT, RLAY, and IMTX Company DescriptionsBlack Diamond Therapeutics NASDAQ:BDTX$2.94 +0.07 (+2.44%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$2.94 0.00 (0.00%) As of 09/5/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Immatics NASDAQ:IMTX$6.26 +0.54 (+9.44%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$6.16 -0.10 (-1.61%) As of 09/5/2025 05:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.Relay Therapeutics NASDAQ:RLAY$4.12 +0.12 (+3.00%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$4.12 +0.00 (+0.12%) As of 09/5/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Rezolute NASDAQ:RZLT$8.00 +0.62 (+8.40%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$8.03 +0.03 (+0.37%) As of 09/5/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
